Low-Dose Involved-Field Radiotherapy in Relapsed Low-Grade Non-Hodgkin's Lymphoma in Elderly Patients (Mansoura University Experience)


Purpose: To assess the response rate, duration of response and prognostic factors affecting response after low-dose involved-field radiotherapy in patients with relapsed low-grade B-cell non-Hodgkin lymphoma. Patients and Methods: Forty-four patients were included. Patients were treated with a total dose of 4 Gy (2 × 2 Gy) using 6 - 15 Mv photon or electron beam. Results: most patients were above age of 60 years (59%) with male predominance. Follicular lymphoma was the most common pathological type; bulky disease (>5 cm) was presented in 61.4%. Patients who received only 2 regimens were 63.7% and 31.8% had >2 involved sites. No treatment related toxicity was observed. The overall response rate was 88.7%; complete response was reached in 59.1% and stable disease in 6.8%, progressive disease in 4.5%. Median time to local progression was 33 months (95% CI 23.70 - 42.29); 2-year local progression free survival was 78%. Response rate was found to be dependent on age, number of involved sites and lymph node size but independent on sex, pathological type, number of prior regimens, LDH level and time since diagnosis. Conclusion: Short-course-low dose palliative radiotherapy (2 × 2 Gy) affords an attractive option for treatment of relapsed low-grade non-Hodgkin’s lymphoma due to high response rates. However, these results had to be confirmed in a larger number of patients.

Share and Cite:

El-Hadaad, H. , Wahba, H. and Awad, I. (2014) Low-Dose Involved-Field Radiotherapy in Relapsed Low-Grade Non-Hodgkin's Lymphoma in Elderly Patients (Mansoura University Experience). Journal of Cancer Therapy, 5, 500-505. doi: 10.4236/jct.2014.56057.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Jemal, A., Siegel, R., Ward, E., et al. (2008) Cancer Statistics, 2008. Cancer Journal for Clinicians, 58, 71-96. http://dx.doi.org/10.3322/CA.2007.0010
[2] Mendenhall, N.P. and Lynch, W. (1995) The Low-Grade Lymphomas. Seminars in Radiation Oncology, 5, 254-266. http://dx.doi.org/10.1016/S1053-4296(05)80025-6
[3] Hiddemann, W., Kneba, M., Dreyling, M., et al. (2005) Front Line Therapy with Rituximab Added to the Combination of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) Significantly Improves the Outcome for Patients with Advanced-Stage Follicular Lymphoma Compared with Therapy with CHOP Alone: Results of a Prospective Randomized Study of the German Low-Grade Lymphoma Study Group. Blood, 106, 3725-3732. http://dx.doi.org/10.1182/blood-2005-01-0016
[4] Marcus, R., Imrie, K., Belch, A., et al. (2005) CVP Chemotherapy plus Rituximab Compared with CVP as First-Line Treatment for Advanced Follicular Lymphoma. Blood, 105, 1417-1423.
[5] Haas, R.L., de Jong, D., Valdes Olmo, S.R.A., et al. (2004) In Vivo Imaging of Radiation Induced Apoptosis in Follicular Lymphoma Patients. International Journal of Radiation Oncology* Biology*Physics, 59, 782-787. http://dx.doi.org/10.1016/j.ijrobp.2003.11.017
[6] Eisenhaurer, E.A., Therasse, P., Bogaerts, J., et al. (2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247.
[7] (2003) Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Seminars in Radiation Oncology, 3, 176-181.
[8] Girinsky, T., Guillot-Vals, D., Koscielny, S., et al. (2001) A High and Sustained Response Rate in Refractory or Relapsing Low-Grade Lymphoma Masses after Low-Dose Radiation: Analysis of Predictive Parameters of Response to Treatment. International Journal of Radiation Oncology* Biology*Physics, 51, 148-155. http://dx.doi.org/10.1016/S0360-3016(01)01626-1
[9] Johannsson, J., Specht, L., Mejer, J., et al. (2002) Phase II Study of Palliative Low-Dose Local Radiotherapy in Disseminated Indolent Non-Hodgiken Lymphoma and Chronic Lymphocytic Leukemia. International Journal of Radiation Oncology*Biology*Physics, 54, 1466-1470.
[10] Haas, R.L., Poortmans, P., de Jong, D., et al. (2003) High Response Rates and Lasting Remissions after Low-Dose Involved Field Radiotherapy in Indolent Lymphomas. Journal of Clinical Oncology, 21, 2474-2480. http://dx.doi.org/10.1200/JCO.2003.09.542
[11] Ng, M., Wirth, A., Ryan, G., et al. (2006) Value of Low-Dose 2 × 2 Gy Palliative Radiotherapy in Advanced Low-Grade Non-Hodgkin’s Lymphoma. Australasian Radiology, 50, 222-227.
[12] Rossier, C., Schick, U., Miralbell, R., et al. (2011) Low-Dose Radiotherapy in Indolent Lymphoma. International Journal of Radiation Oncology*Biology*Physics, 81, e 1-6.
[13] Chan, E.K., Fung, S., Gospodarowicz, M., et al. (2010) Low Dose Radiation Treatment of Lymphoma Tumors. International Journal of Radiation Oncology*Biology*Physics, 81, e781-786.
[14] Luthy, S.K., Ng, A.K., Silver, B., et al. (2008) Response to Low-Dose Involved-Field Radiotherapy in Patients with Non-Hodgkin’s Lymphoma. Annals of Oncology, 19, 2043-2047.
[15] Webster, K. and Cella, D. (1998) Quality of Life in Patients with Low-Grade non-Hodgkin’s Lymphoma. Oncology, 12, 697-714.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.